Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2001
08/09/2001WO2001002017A3 Erythropoietin conjugates with polyethylenglycol
08/09/2001WO2001002006A3 Fertility impairing vaccine containing avian zona pellucida protein and method of use
08/09/2001WO2001000798A3 Cloning and expressing of human cathepsin k in mammalian cells
08/09/2001WO2000073324A9 Modulation of gene expression in gastrointestinal inflammation
08/09/2001WO2000070046A9 Secreted polypeptides and corresponding polynucleotides
08/09/2001WO2000069895A3 Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins
08/09/2001WO2000067728A3 Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
08/09/2001WO2000064941A3 G-protein coupled receptor and method of using same
08/09/2001WO2000064456A3 Substitution infusion fluid and citrate anticoagulation
08/09/2001WO2000063351A3 Carbohydrate-modifying enzymes
08/09/2001WO2000062813A3 Cationic peg-lipids and methods of use
08/09/2001WO2000061729A3 Regulation of the expression of transcriptional repressor genes using nucleic acid molecules
08/09/2001WO2000056924A3 Genomic sequence of the purh gene and purh-related biallelic markers
08/09/2001WO2000050452A9 Mutants of rac protein
08/09/2001WO2000037643A3 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
08/09/2001US20010013134 Transgenic mammal; polynucleotide containing pancreas promoter
08/09/2001US20010012890 Administering caveolin antibody nucleic acid
08/09/2001US20010012889 36 human secreted proteins
08/09/2001US20010012885 Conjugate consisting of an active substance and a non-exogeneous native protein
08/09/2001US20010012856 Compositions and methods for the treatment of anorectal disorders
08/09/2001US20010012837 Anti-ulcer composition
08/09/2001US20010012836 Determining the presence or absence of a mutation in the nucleotide sequence or absence of a mutation in nucleotide sequence encoding the specific polypeptides in the genome of the subject and analyzing for presence of polypeptide
08/09/2001US20010012835 Transducing a target cell with a nucleic acid sequence encoding a dCK protein (deoxycytidine kinase) having phosphorylation activity operably linked to a promoter
08/09/2001US20010012833 Method for treating neuromuscular disorders and conditions with botulinum toxin types A and B
08/09/2001US20010012832 Replenishing melatonin, thymus, thyroid, adrenal and sex hormones to predetermined levels in conjunction with the human growth hormone
08/09/2001US20010012831 Calcium-binding protein
08/09/2001US20010012830 Combination therapy method for treating chronic hepatitis B
08/09/2001US20010012829 Transepithelial delivery GLP-1 derivatives
08/09/2001US20010012828 Intraspinal botulinum toxin for treating pain
08/09/2001US20010012626 Polynucleotides encoding Presenilin 1 (PS1); diagnosing a patient having an increased likelihood of contracting Alzheimer's disease
08/09/2001US20010012625 Ngf variants
08/09/2001US20010012624 Polynucleotides, vectors, host cells; for research, diagnosis and clinical use
08/09/2001US20010012621 Determining the expression of lysyl oxidase, the expression of lysyl oxidase indicating that the compound is capable of suppressing ras functions
08/09/2001US20010012515 Isolated polypeptide
08/09/2001US20010012514 Neutralizing, removal antibodies
08/09/2001US20010012513 Embryonic or stem-like cell lines produced by cross species nuclear transplantation
08/09/2001US20010012506 Endothelial-derived toxic factor
08/09/2001DE10005275A1 Neuartige Glycokonjugate Novel glycoconjugates
08/09/2001DE10004930A1 Gene encoding a protein of the G protein receptor super family, having homology to neurotransmitter receptors is useful to develop new medicaments
08/09/2001DE10004667A1 Neues ß-Defensin, hBD-3, Herstellung und seine Anwendung New beta-defensin hBD-3, Processing and its Application
08/09/2001DE10003653A1 Vektorkonstrukte zur gentherapeutisch vermittelten Radioiodtherapie entdifferenzierter und medullärer Schilddrüsen-Karzinome sowie nicht-thyreoidaler Tumore und ihrer Metastasen Vector constructs for gene therapy mediated radioiodine therapy of medullary thyroid carcinoma and dedifferentiated and non-thyroidal tumors and their metastases
08/09/2001CA2762121A1 The use of bicyclo [3.2.1]octan or kaurene for the treatment of non-insulin dependent diabetes mellitus, hypertension and metabolic syndrome
08/09/2001CA2399982A1 G-protein coupled receptors
08/09/2001CA2399809A1 Combinatorial protein domains
08/09/2001CA2399792A1 Substituted amino acids as neutral sphingomyelinase inhibitors
08/09/2001CA2399776A1 Novel nucleic acids and polypeptides
08/09/2001CA2399727A1 Narc-1, subtilase-like homologs
08/09/2001CA2399686A1 Methods and materials relating to cub domain polypeptides and polynucleotides
08/09/2001CA2399681A1 Methods and materials relating to alpha-2-macroglobulin-like polypeptides and polynucleotides
08/09/2001CA2399672A1 Methods and materials relating to metallocarboxypeptidase-like polypeptides and polynucleotides
08/09/2001CA2399652A1 Methods and materials relating to neuronal guidance molecule-like (ngm-like) polypeptides and polynucleotides
08/09/2001CA2399649A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides
08/09/2001CA2399644A1 Methods and materials relating to neurotrimin-like polypeptides and polynucleotides
08/09/2001CA2399509A1 Melanin-concentrating hormone analogs
08/09/2001CA2399267A1 Protein c derivatives
08/09/2001CA2399098A1 Pharmaceutical carrier composition for papayne based products
08/09/2001CA2399080A1 Humanized anti-ccr2 antibodies and methods of use therefor
08/09/2001CA2399063A1 A method for maintaining or improving the synthesis of mucins
08/09/2001CA2399058A1 Targeting peptides
08/09/2001CA2399052A1 Screening method
08/09/2001CA2399032A1 Ligands for fpr class receptors that induce a host immune response to a pathogen or inhibit hiv infection
08/09/2001CA2399026A1 Mucin-1 derived antigens and their use in immunotherapy
08/09/2001CA2399022A1 Ligand for vascular endothelial growth factor receptor
08/09/2001CA2398998A1 Cd40-binding apc-activating molecules
08/09/2001CA2398995A1 Lipid hydrolysis therapy for atherosclerosis and related diseases
08/09/2001CA2398957A1 Human herpesvirus 6a and 6b transfer factors for the treatment of chronic fatigue syndrome and multiple sclerosis
08/09/2001CA2398900A1 Therapeutic agents for opthalmopathy
08/09/2001CA2398889A1 Antisense modulation of survivin expression
08/09/2001CA2398877A1 Nucleic acids, proteins, and antibodies
08/09/2001CA2398678A1 Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr
08/09/2001CA2398255A1 Bcl-2-like polynucleotides, polypeptides, and antibodies
08/09/2001CA2398215A1 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides
08/09/2001CA2396782A1 Shell-and-core dosage form approaching zero-order drug release
08/09/2001CA2396774A1 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
08/09/2001CA2369056A1 Vmip-ii peptide antagonists of cxcr4
08/08/2001EP1122312A1 Novel protein war-1 and gene thereof
08/08/2001EP1122311A1 Remedies for neuropathy containing as the active ingredient galectin-1 or its derivatives
08/08/2001EP1122307A1 Human carnosinase 2
08/08/2001EP1122306A1 Novel deoxyribonuclease, gene encoding the same and use thereof
08/08/2001EP1122262A1 Neovascular-specific peptides
08/08/2001EP1121941A1 Sorbefacients and preparations for percutaneous absorption containing the same
08/08/2001EP1121936A1 Preventives and/or remedies for obesity
08/08/2001EP1121935A1 Pharmaceutical composition containing a small or medium size peptide
08/08/2001EP1121464A1 Polymorphism in a tgf-ss gene correlated to osteoporosis
08/08/2001EP1121456A1 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction
08/08/2001EP1121454A1 Extracellular novel rage binding protein (en-rage) and uses thereof
08/08/2001EP1121449A1 Delivery system for porcine somatotropin
08/08/2001EP1121448A1 EXPRESSION AND SECRETION OF icIL-1 RECEPTOR ANTAGONIST TYPE II
08/08/2001EP1121444A2 Protein kinase homologs
08/08/2001EP1121442A2 Recombinant e1a deleted adenoviral vectors
08/08/2001EP1121439A2 Methods and compositions for inhibiting neoplastic cell growth
08/08/2001EP1121438A2 p53 BINDING AREAS
08/08/2001EP1121436A2 Non-desensitizing ampa-receptors
08/08/2001EP1121435A1 Camel, an alternative translation product of the tumour antigen lage-1
08/08/2001EP1121434A1 A method of modulating cell survival and reagents useful for same
08/08/2001EP1121433A2 Human ankyrin family protein
08/08/2001EP1121431A1 Non-endogenous, constitutively activated human g protein-coupled receptors
08/08/2001EP1121430A1 Human isre-binding protein
08/08/2001EP1121429A2 Gene therapy of alzheimer's disease by delivery of an encoded apolipoprotein e
08/08/2001EP1121427A1 (mbp1) polypeptides capable of interacting with oncogenic mutants of the p53 protein